deferoxamine has been researched along with Cardiovascular Stroke in 17 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, our goal was to test if the association of N-acetylcysteine (NAC) and an iron chelator (deferoxamine--DFX) in a rodent model of acute myocardial infarction (AMI) improves cardiac function." | 7.81 | N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction. ( Andrades, M; Biolo, A; Clausell, N; Cohen, C; Dal-Pizzol, F; Lopes, A; Martinelli, N; Olsen, V; Phaelante, A; Rohde, LE; Tobar, SA, 2015) |
| "Ga-67-DFO-DAS-fibrinogen (Ga-fbg) scintigraphy, a new radiopharmaceutical method, was performed for detecting intraventricular thrombi following acute myocardial infarction in five patients." | 7.67 | [Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen]. ( Akioka, K; Hirota, K; Itagane, H; Ochi, H; Oku, H; Takeda, T; Takeuchi, K; Teragaki, M; Yasuda, M, 1988) |
| "Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size." | 5.16 | Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction. ( Chan, W; Croft, KD; Dart, AM; Duffy, SJ; Ellims, AH; Kaye, DM; Kingwell, BA; Lefkovits, L; Mori, T; Natoli, A; Taylor, AJ; Wong, C, 2012) |
| " Thus, our goal was to test if the association of N-acetylcysteine (NAC) and an iron chelator (deferoxamine--DFX) in a rodent model of acute myocardial infarction (AMI) improves cardiac function." | 3.81 | N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction. ( Andrades, M; Biolo, A; Clausell, N; Cohen, C; Dal-Pizzol, F; Lopes, A; Martinelli, N; Olsen, V; Phaelante, A; Rohde, LE; Tobar, SA, 2015) |
| "Ga-67-DFO-DAS-fibrinogen (Ga-fbg) scintigraphy, a new radiopharmaceutical method, was performed for detecting intraventricular thrombi following acute myocardial infarction in five patients." | 3.67 | [Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen]. ( Akioka, K; Hirota, K; Itagane, H; Ochi, H; Oku, H; Takeda, T; Takeuchi, K; Teragaki, M; Yasuda, M, 1988) |
| "The deferoxamine dose was five times greater than the maximally tolerated dose of free deferoxamine." | 2.67 | High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size. ( Hallaway, PE; Hedlund, BE; Horwitz, LD; Lesnefsky, EJ, 1990) |
| "Deferoxamine pretreatment also decreased (P less than ." | 1.28 | Deferoxamine pretreatment reduces canine infarct size and oxidative injury. ( Horwitz, LD; Lesnefsky, EJ; Repine, JE, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigo, R | 1 |
| Prieto, JC | 1 |
| Aguayo, R | 1 |
| Ramos, C | 1 |
| Puentes, Á | 1 |
| Gajardo, A | 1 |
| Panieri, E | 1 |
| Rojas-Solé, C | 1 |
| Lillo-Moya, J | 1 |
| Saso, L | 1 |
| Shen, Y | 1 |
| Shen, X | 1 |
| Wang, S | 1 |
| Zhang, Y | 1 |
| Wang, Y | 1 |
| Ding, Y | 1 |
| Shen, J | 2 |
| Zhao, J | 1 |
| Qin, H | 1 |
| Xu, Y | 1 |
| Zhou, Q | 1 |
| Wang, X | 1 |
| Tu, H | 1 |
| Zhou, YJ | 1 |
| Tang, LJ | 1 |
| Xiong, XM | 1 |
| Zhang, XJ | 1 |
| Ali Sheikh, MS | 1 |
| Zhang, JJ | 1 |
| Luo, XJ | 1 |
| Yuan, C | 2 |
| Peng, J | 1 |
| Xie, P | 1 |
| Yang, L | 1 |
| Talaiti, A | 1 |
| Wu, JJ | 1 |
| Yu, J | 1 |
| Yu, T | 1 |
| Wang, HY | 1 |
| Huang, B | 1 |
| Wu, Q | 1 |
| Maimaitili, Y | 1 |
| Wang, J | 1 |
| Ma, HP | 1 |
| Yang, YN | 1 |
| Zheng, H | 1 |
| Wang, H | 1 |
| Yuan, Z | 1 |
| Phaelante, A | 1 |
| Rohde, LE | 1 |
| Lopes, A | 1 |
| Olsen, V | 1 |
| Tobar, SA | 1 |
| Cohen, C | 1 |
| Martinelli, N | 1 |
| Biolo, A | 1 |
| Dal-Pizzol, F | 1 |
| Clausell, N | 1 |
| Andrades, M | 1 |
| Chan, W | 1 |
| Taylor, AJ | 1 |
| Ellims, AH | 1 |
| Lefkovits, L | 1 |
| Wong, C | 1 |
| Kingwell, BA | 1 |
| Natoli, A | 1 |
| Croft, KD | 1 |
| Mori, T | 1 |
| Kaye, DM | 1 |
| Dart, AM | 1 |
| Duffy, SJ | 1 |
| Dendorfer, A | 1 |
| Heidbreder, M | 1 |
| Hellwig-Bürgel, T | 1 |
| Jöhren, O | 1 |
| Qadri, F | 1 |
| Dominiak, P | 1 |
| Watanabe, BI | 1 |
| Limm, W | 1 |
| Suehiro, A | 1 |
| Suehiro, G | 1 |
| Premaratne, S | 1 |
| McNamara, JJ | 1 |
| Chopra, K | 1 |
| Singh, M | 1 |
| Kaul, N | 1 |
| Andrabi, KI | 1 |
| Ganguly, NK | 1 |
| Lesnefsky, EJ | 2 |
| Hedlund, BE | 1 |
| Hallaway, PE | 1 |
| Horwitz, LD | 2 |
| Reddy, BR | 2 |
| Wynne, J | 1 |
| Kloner, RA | 2 |
| Przyklenk, K | 2 |
| Kobayashi, S | 1 |
| Tadokoro, H | 1 |
| Wakida, Y | 1 |
| Kar, S | 1 |
| Nordlander, R | 1 |
| Haendchen, RV | 1 |
| Corday, E | 1 |
| Klibanov, AL | 1 |
| Khaw, BA | 1 |
| Nossiff, N | 1 |
| O'Donnell, SM | 1 |
| Huang, L | 1 |
| Slinkin, MA | 1 |
| Torchilin, VP | 1 |
| Repine, JE | 1 |
| Itagane, H | 1 |
| Hirota, K | 1 |
| Teragaki, M | 1 |
| Akioka, K | 1 |
| Yasuda, M | 1 |
| Oku, H | 1 |
| Takeuchi, K | 1 |
| Takeda, T | 1 |
| Ochi, H | 1 |
1 review available for deferoxamine and Cardiovascular Stroke
| Article | Year |
|---|---|
Joint Cardioprotective Effect of Vitamin C and Other Antioxidants against Reperfusion Injury in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Biomarkers; Deferoxamine; Dose-Response Relati | 2021 |
2 trials available for deferoxamine and Cardiovascular Stroke
| Article | Year |
|---|---|
Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction.
Topics: Aged; Angioplasty; Chelating Agents; Coronary Vessels; Deferoxamine; Echocardiography; Electrocardio | 2012 |
High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size.
Topics: Analysis of Variance; Animals; Deferoxamine; Dogs; Dose-Response Relationship, Drug; Double-Blind Me | 1990 |
14 other studies available for deferoxamine and Cardiovascular Stroke
| Article | Year |
|---|---|
Protective effects of Salvianolic acid B on rat ferroptosis in myocardial infarction through upregulating the Nrf2 signaling pathway.
Topics: Animals; Deferoxamine; Ferroptosis; Iron; Lipid Peroxides; Myocardial Infarction; NF-E2-Related Fact | 2022 |
Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis.
Topics: Animals; Cell Line; Deferoxamine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; | 2021 |
Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats.
Topics: Anesthetics, Inhalation; Animals; Deferoxamine; Diabetes Mellitus, Experimental; Gene Expression Reg | 2017 |
Ginsenoside Rg1 inhibits myocardial ischaemia and reperfusion injury
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Deferoxamine; Diabetes Mellitus, Experimental; Extracellul | 2019 |
N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction.
Topics: Acetylcysteine; Aldehydes; Animals; Antioxidants; Deferoxamine; Echocardiography; Immunohistochemist | 2015 |
Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals.
Topics: Aldehyde Reductase; Alkaloids; Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix- | 2005 |
Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury.
Topics: Animals; Deferoxamine; Disease Models, Animal; Electrocardiography; Female; Free Radicals; Hydroxyl | 1993 |
Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative effect.
Topics: Animals; Deferoxamine; Female; Free Radicals; In Vitro Techniques; Luminescent Measurements; Male; M | 1992 |
Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury.
Topics: Animals; Blood Pressure; Deferoxamine; Dogs; Echocardiography; Female; Iron; Male; Myocardial Infarc | 1991 |
Coronary venous retroinfusion of deferoxamine reduces infarct size in pigs.
Topics: Animals; Cardiac Catheterization; Coronary Vessels; Deferoxamine; Female; Free Radical Scavengers; I | 1991 |
Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain.
Topics: Animals; Antibodies, Monoclonal; Chelating Agents; Deferoxamine; Drug Carriers; Liposomes; Macromole | 1991 |
Deferoxamine pretreatment reduces canine infarct size and oxidative injury.
Topics: Animals; Coronary Disease; Coronary Vessels; Deferoxamine; Dogs; Glutathione; Hemodynamics; Male; My | 1990 |
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury.
Topics: Animals; Coronary Circulation; Coronary Vessels; Deferoxamine; Dogs; Female; Hemodynamics; Infusions | 1989 |
[Detection of left ventricular thrombi after acute myocardial infarction using Ga-67-DFO-DAS-fibrinogen].
Topics: Adult; Deferoxamine; Echocardiography; Female; Fibrinogen; Gallium Radioisotopes; Heart Diseases; He | 1988 |